Chang H. Ahn

Dr. Chang H. Ahn (Chang Ahn or Chang-Ho Ahn) is the Chairman and Chief Executive Officer of Rexahn Pharmaceuticals, Inc., a publicly listed company (NYSE AMEX: RNN) developing medicines for life-threatening or debilitating diseases such as cancer and brain disorders. Dr. Ahn founded Rexahn in 2001 and led the company to public listing on the American Stock Exchange in 2008, which subsequently merged with the New York Stock Exchange. In 2008, Rexahn was also selected as Russell 2000 Index company.

Education ^[1]

• Bachelor of Science in pharmacy, Seoul National University
• Bachelor of Science in pharmacy, Creighton University
• Doctor of Philosophy in pharmacology, Ohio State University

Research

• 1985-1986 Emory University’s School of Medicine (Atlanta, Georgia)
• 1988-2001 National Cancer Institute of National Institutes of Health, Bethesda, Maryland
• 1988-2001 Food and Drug Administration (Rockville, Maryland)

During his 13 year tenure as a regulatory officer at Food and Drug Administration, Dr. Ahn represented the federal agency in the field of DNA therapeutics and cancer multi-drug resistance, co-authored/authored several federal guidelines for new drug development, and advised the pharmaceutical industry. Dr. Ahn also served a lab chief in a research group during his career at the U.S. Food and Drug Administration (FDA).

Following founding Rexahn, Dr. Ahn led the discovery of drugs targeting key cellular communication systems, including protein kinase Akt and transcription factor HIF-1. An Akt inhibitor discovered is in clinical development against advanced cancers. Dr. Ahn also led a team of scientists and clinicians to develop neuroprotective medicines for Parkinson's and Alzheimer's diseases. He is an author of over 60 research articles, and holds 6 patents as well as several pending patents

Contributions

• Founder, The Society of Biomedical Research (1990)
• Founder & Chairman, Rexahn Pharmaceuticals, Inc. (2001–present)
• President, The Society of Biomedical Research (2001–2004)
• Organizing Chair, Osong International Bio-Expo (2002)
• General Chairman, The US-Korea Bio Business & Partnership Forum (2003, 2004)
• Editor-in-Chief, The Journal of Biomedical Research (1991–2000)
• Review Editor, the Archives of Pharmaceutical Research (1995–1998)
• Contributor, Mae-Il Economic Daily (2002)
• Honorary citizen, Chung-Buk Province, Korea (2003)
• Listee, Marquis Who's Who in America, Who's Who in America - Science and Engineering. (2006)

Bibliography

1. "Clavulanic acid stimulates sexual behaviour in male rats," Eur. J. Pharmacol. 609(1-3), 69 (2009).

2. "In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047," J. Cell Biochem. 104(3), 985 (2008).

3. "A Phase I Trial of RX-0201 (Archexin; Akt-1 Antisense) in Patients With An Advanced Cancer,"in 2007).

4. "Clavulanic acid: a competitive inhibitor of beta-lactamases with novel anxiolytic-like activity and minimal side effects," Pharmacol. Biochem. Behav. 93(2), 112 (2009).

5. "QSID Tool: a new three-dimensional QSAR environmental tool," J. Comput. Aided Mol. Des 22(12), 873 (2008).

6. "Requirement of hCenexin for proper mitotic functions of polo-like kinase 1 at the centrosomes," Mol. Cell Biol. 26(22), 8316 (2006).

7. "Design, synthesis, and anticancer activity of fluorocyclopentenyl-pyrimidines," Nucleic Acids Symp. Ser. (Oxf) (49), 107 (2005).

References

1. ^ www.rexahn.com

External links

• Rexahn Company Website